Demonstrates non-inferior outcomes following a single dose switch to ranibizumab in neovascular AMD, suggesting future treatment strategies.
Our study indicates that changes in CMT are affected by age, the number of previous injections, and the time interval between visits. These biomarkers may offer valuable insights for future research on switching anti-VEGF drugs to optimize treatment strategies for nAMD. A single dose treatment switch to ranibizumab yielded non-inferior outcomes.
No takes yet. Share an insight, caveat, or question.
Iby et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: